Company SCYNEXIS, Inc.

Equities

SCYX

US8112922005

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
1.47 USD +3.16% Intraday chart for SCYNEXIS, Inc. +5.00% -34.08%

Business Summary

SCYNEXIS, Inc. is a biotechnology company. The Company is developing its lead product candidate, ibrexafungerp, as a broad-spectrum, intravenous (IV)/oral agent for multiple fungal indications in both the community and hospital settings. Its Ibrexafungerp has demonstrated activity against a large collection of medically relevant strains of Candida and Aspergillus genera, including multidrug-resistant strains, as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera. The Company has received approval from the United States Food and Drug Administration (FDA) for the New Drug Application (NDA) for BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC, also known as vaginal yeast infection), and for the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC), respectively.

Number of employees: 36

Sales per Business

USD in Million2021Weight2022Weight Delta
Innovative Medicines
100.0 %
13 100.0 % 5 100.0 % -61.32%

Sales per region

USD in Million2021Weight2022Weight Delta
United States
100.0 %
13 100.0 % 5 100.0 % -61.32%

Managers

Managers TitleAgeSince
Chief Executive Officer 59 15-05-31
Director of Finance/CFO 63 22-10-23
Chief Tech/Sci/R&D Officer - 20-09-30
Chief Tech/Sci/R&D Officer - 19-06-09
Investor Relations Contact - 21-07-31
General Counsel - 16-12-31
General Counsel 46 17-11-14

Members of the board

Members of the board TitleAgeSince
Director/Board Member 66 19-01-20
Director/Board Member 62 15-09-23
Director/Board Member 71 08-11-30
Chairman 65 14-11-26
Director/Board Member 71 15-02-24
Chief Executive Officer 59 15-05-31
Director/Board Member 60 19-12-12

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 37,207,799 36,135,699 ( 97.12 %) 0 97.12 %

Shareholders

NameEquities%Valuation
Federated Global Investment Management Corp.
12.91 %
4,804,700 12.91 % 8 M $
Kingdon Capital Management LLC
6.012 %
2,237,048 6.012 % 4 M $
Vanguard Global Advisers LLC
4.189 %
1,558,517 4.189 % 3 M $
Avidity Partners Management LP
3.894 %
1,448,728 3.894 % 2 M $
Stonepine Capital Management LLC
3.642 %
1,355,186 3.642 % 2 M $
Decheng Capital LLC
1.493 %
555,555 1.493 % 899 999 $
AMH Equity Ltd.
1.479 %
550,400 1.479 % 891 648 $
D. A. Davidson & Co.
1.415 %
526,490 1.415 % 852 914 $
479,871 1.290 % 777 391 $
BlackRock Institutional Trust Co. NA
1.149 %
427,575 1.149 % 692 672 $

Company contact information

SCYNEXIS, Inc.

1 Evertrust Plaza 13th floor

07302-6548, Jersey City

+201 884 5485

http://www.scynexis.com
address SCYNEXIS, Inc.(SCYX)
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.47 USD
Average target price
7.125 USD
Spread / Average Target
+384.69%
Consensus